Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

(Bloomberg) -- Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may ...

(Bloomberg) -- A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders. The death occurred on Dec. 14 after the ...

US-based pharmaceutical giant Pfizer is set to cut hundreds of jobs in Switzerland as part of the company's multi-year cost reduction program, reported the news agency Bloomberg, citing people aware ...

Pfizer‘s better-than-expected earnings report wasn’t enough to blow away the gloom that has settled over the stock, but shares rose on the CEO’s optimism that anticipated drug tariff’s won’t have a ...